Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Sun Pharma, Emcure, Dr...

    Sun Pharma, Emcure, Dr Reddys added in US price-fixing probe

    Written by supriya kashyap kashyap Published On 2017-11-01T11:45:43+05:30  |  Updated On 1 Nov 2017 11:45 AM IST
    Sun Pharma, Emcure, Dr Reddys added in US price-fixing probe

    New York: Prosecutors announced they added 12 more companies and two executives as targets in a wide-ranging antitrust investigation that charges generic drug manufacturers fixed drug prices.


    The suit, which was filed in December and is now supported by prosecutors from 45 US states, alleges a broad conspiracy by Mylan Pharmaceuticals, Teva Pharmaceuticals and others to divvy up markets and set prices to boost profits at consumer's expense.


    On Tuesday, attorneys general from the 45 states asked a federal court to allow them to increase the number of generic drug manufacturer defendants from six to 18, increase the number of drugs at issue in the litigation and name two executives as defendants.


    The executives are Mylan president Rajiv Malik and Satish Mehta, chief executive of Emcure Pharmaceuticals, parent company of Heritage Pharmaceuticals.


    "When that complaint was filed, I said it was just the tip of the iceberg," said Connecticut Attorney General George Jepsen, who first began probing generic drug price increases in 2014.


    "Today, we are seeking leave of the court to file an expanded complaint that implicates significantly more companies, significantly more drugs and two individual executives in the illegal conduct."


    "Generic drugs are a multibillion-dollar industry," Jepsen said, "but it's an industry based on products that people need and rely upon every single day. The allegations of our complaint are shocking, and the depth and breadth of the conspiracies alleged are mind-blowing."


    Besides Mylan, Teva and Heritage, the initial complaint named Aurobindo Pharma USA, Inc., Citron Pharma, and Mayne Pharma.


    On Tuesday, the prosectors proposed adding Actavis Holdco, Actavis Pharma, Ascend Laboratories, Apotex Corp., Dr. Reddy's Laboratories, Inc., Emcure Pharmaceuticals, Glenmark Pharmaceuticals, Lannett Company, Par Pharmaceutical Companies, Sandoz, Sun Pharmaceutical Industries, and Zydus Pharmaceuticals(USA).

    Dr Reddy'sEmcureemcure pharmaceuticalsfixed drug pricegeneric drugHERITAGEMylanprobeProsecutorsRajiv MalikSatish MehtaSun PharmaTevazydus
    Source : AFP

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok